WO1991001329A1 - Polypeptide inhibitor of viral replication - Google Patents
Polypeptide inhibitor of viral replication Download PDFInfo
- Publication number
- WO1991001329A1 WO1991001329A1 PCT/GB1990/001143 GB9001143W WO9101329A1 WO 1991001329 A1 WO1991001329 A1 WO 1991001329A1 GB 9001143 W GB9001143 W GB 9001143W WO 9101329 A1 WO9101329 A1 WO 9101329A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vmw
- amino acids
- sequence
- polypeptide
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/224—Herpes related
Definitions
- This invention relates to a polypeptide which inhibits the replication of Herpes Simplex Virus (HSV) and like viruses and its therapeutic use against infections of such viruses.
- HSV Herpes Simplex Virus
- HSV exists as several serotypes of which HSV-1 is one which is clinically significant in relation to cold sores.
- Vmw 65 The IE genes of HSV are induced by a component of the virion, first identified by M.E.M. Campbell, J.W. Palfreyman and CM. Preston, Journal of Molecular Biology 1SQ, 1-19 (1984), as "Vmw 65".
- Vmw 65 which has also been referred to as VP16, is a tegument protein which lies between the viral membrane and the capsid.
- Vmw 65 is said to be "trans-acting" or "trans- activating”. This language indicates merely that it is some soluble factor which acts on the viral DNA to regulate it.
- Yet another name for Vmw 65 is the ⁇ -Trans Inducing Factor or ⁇ -TIF, meaning that it acts on the viral DNA to induce transcription of the IE ( ⁇ ) genes.
- Vmw 65 might bind to the DNA in the TAATGARAT region, either directly or indirectly by modifying a host cell polypeptide.
- the TAATGARAT region which is termed a "cis-acting site" or the ⁇ -Trans Induction Cis-acting ( ⁇ -TIC) site, does not bind directly to Vmw 65, but does bind to one or more host cell proteins.
- TRF TAATGARAT Recognition Factor
- Vmw 65 indicates the induction of IE genes by associating with cellular proteins, to form a complex known as IEC or TRF.C, which is able to bind specifically to DNA sequences which include TAATGARAT.
- IE gene induction involves a complex " which is at least ternary between, at least, Vmw 65, TRF and a TAATGARAT region sequence.
- Vmw 65 structure and function using measurements of the expression of a £&i gene linked to an IE promoter region as an- assay for the transcriptional induction function of Vmw 65. They found a total loss of IE induction activity when 4 or 5 amino acids were inserted into the Vmw 65 coding sequence at amino acids 178, 215, 335, 369 or 471 or when Vmw 65 was deleted in any of the following regions : amino acids 26-140, 26-177, 26-240, 142-177, 174-240, 179-412, 242-412, 331-412 and 331-470.
- TRF.C complex formation is inhibited by a polypeptide which consists of or includes the region of about amino acids 366 or 367 to 373 of Vmw 65.
- the boundaries of the critical region have not yet been defined with absolute precision and it cannot be ruled out that one might be able to dispense with one or two amino acids at either end of this chain. More probably, however, the polypeptide would have to be made longer to achieve the best inhibition, particularly at the C-terminal (373) end.
- Particularly preferred is a polypeptide which consists of or includes the amino acids 360 to 390, especially 366 or 367 to 388, 389 or 390.
- amino acid sequence is as follows (identified as SEQ ID NO: 1):
- polypeptides of the invention should not be longer than 40 amino acids, most preferably not longer than 30. These are purely arbitrary numbers.
- the invention includes the polypeptide per se, together with conservatively modified variants thereon, and its use as an inhibitor of any virus which depends for its action on a Vmw 65- like protein, but, of course, particularly for Herpes Simplex
- Viruses and especially HSV type 1 are especially HSV type 1.
- the invention further includes antibodies to the polypeptides of the invention and their use as inhibitors of viral replication and for other purposes. Description of the preferred embodiments
- the inventive concept has at its heart an experimental showing that the polypeptide consisting of amino acids 360-373 is an inhibitor of IE gene induction in HSV.
- This sequence could be cut back at its N-terminal end and/or extended at its C-terminal end derives from other evidence.
- experiments have been carried out with deletion mutants of Vmw 65 made by deletions which start at the C-terminus and extend progressively towards the N-terminus. These mutants were made in the Vmw 65 gene by progressively chewing back the gene from its 3'-end with Bal31.
- Polypeptides of the invention can be prepared by routine methods of synthesis, well known to those in the peptide field.
- the polypeptides can be administered parenterally in a suitable inert diluent at a dose typically within the range 0.1 to 15 g. per day.
- Topical administration, as an ointment or cream is also contemplated.
- the invention also includes antibodies to the polypeptides of the invention, whether polyclonal, monoclonal or made by antibody engineering. Such antibodies are potentially of therapeutic value to block the Vmw 65 directly and also useful in the diagnosis of herpes virus infections.
- Vmw 65 for a two site or sandwich assay
- a labelled antibody directed to another epitope of Vmw 65 being used for detection of the captured Vmw 65.
- the invention is particularly applicable to the human Herpes Simplex Viruses Type 1 and 2 and to other herpes viruses which depend on Vmw 65 or a protein which is closely homologous in the relevant amino acid region for binding to a cellular factor to form a complex which induces IE gene expression.
- Vmw 65 or a protein which is closely homologous in the relevant amino acid region for binding to a cellular factor to form a complex which induces IE gene expression.
- the following Example illustrates the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90911594A EP0484406B1 (en) | 1989-07-25 | 1990-07-25 | Polypeptide inhibitor of viral replication |
JP90510899A JPH05505387A (en) | 1989-07-25 | 1990-07-25 | Polypeptide inhibitors of viral replication |
DE69010910T DE69010910T2 (en) | 1989-07-25 | 1990-07-25 | VIRAL REPLICATION POLYPEPTIDE INHIBITORS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898917029A GB8917029D0 (en) | 1989-07-25 | 1989-07-25 | Polypeptide inhibitor of viral replication |
GB8917029.4 | 1989-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991001329A1 true WO1991001329A1 (en) | 1991-02-07 |
Family
ID=10660615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/001143 WO1991001329A1 (en) | 1989-07-25 | 1990-07-25 | Polypeptide inhibitor of viral replication |
Country Status (11)
Country | Link |
---|---|
US (1) | US5245010A (en) |
EP (2) | EP0484406B1 (en) |
JP (1) | JPH05505387A (en) |
AT (1) | ATE108802T1 (en) |
AU (1) | AU637389B2 (en) |
CA (1) | CA2063801A1 (en) |
DE (1) | DE69010910T2 (en) |
GB (2) | GB8917029D0 (en) |
IE (1) | IE65588B1 (en) |
WO (1) | WO1991001329A1 (en) |
ZA (1) | ZA905809B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0541692A1 (en) * | 1990-08-02 | 1993-05-19 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633152A (en) * | 1988-06-24 | 1997-05-27 | Carnegie Institution Of Washington | Method of controlling viral growth |
GB9119940D0 (en) * | 1991-09-18 | 1991-10-30 | Hare Peter F J O | Polypeptide inhibitor of viral replication |
AU699168B2 (en) * | 1993-07-09 | 1998-11-26 | University Of Pittsburgh | Selection and use of antiviral peptides |
WO1995032307A1 (en) * | 1994-05-20 | 1995-11-30 | Tularik, Inc. | Epstein-barr virus transcription factor binding assay |
CA2538794C (en) | 2003-09-12 | 2016-04-19 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
-
1989
- 1989-07-25 GB GB898917029A patent/GB8917029D0/en active Pending
-
1990
- 1990-07-24 ZA ZA905809A patent/ZA905809B/en unknown
- 1990-07-24 IE IE268590A patent/IE65588B1/en not_active IP Right Cessation
- 1990-07-25 EP EP90911594A patent/EP0484406B1/en not_active Expired - Lifetime
- 1990-07-25 EP EP90308135A patent/EP0410713A1/en active Pending
- 1990-07-25 JP JP90510899A patent/JPH05505387A/en active Pending
- 1990-07-25 DE DE69010910T patent/DE69010910T2/en not_active Expired - Fee Related
- 1990-07-25 AU AU60710/90A patent/AU637389B2/en not_active Ceased
- 1990-07-25 AT AT90911594T patent/ATE108802T1/en not_active IP Right Cessation
- 1990-07-25 WO PCT/GB1990/001143 patent/WO1991001329A1/en active IP Right Grant
- 1990-07-25 CA CA002063801A patent/CA2063801A1/en not_active Abandoned
- 1990-07-25 GB GB9016377A patent/GB2234246B/en not_active Expired - Lifetime
- 1990-07-25 US US07/820,658 patent/US5245010A/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Proc. Natl. Acad. Sci. USA, Volume 82, 1985, P.E. PELLETT et al.: "Nucleotide Sequence and Predicted Amino Acid Sequence of a Protein Encoded in a Small Herpes Simplex Virus DNA Fragment Capable of Trans-Inducting alpha Genes", pages 5870-5874 see the whole article * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0541692A1 (en) * | 1990-08-02 | 1993-05-19 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
EP0541692A4 (en) * | 1990-08-02 | 1993-12-08 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
Also Published As
Publication number | Publication date |
---|---|
ZA905809B (en) | 1992-03-25 |
CA2063801A1 (en) | 1991-01-26 |
JPH05505387A (en) | 1993-08-12 |
DE69010910T2 (en) | 1994-12-01 |
EP0484406A1 (en) | 1992-05-13 |
GB2234246B (en) | 1993-03-17 |
ATE108802T1 (en) | 1994-08-15 |
GB9016377D0 (en) | 1990-09-12 |
IE902685A1 (en) | 1991-02-27 |
GB2234246A (en) | 1991-01-30 |
DE69010910D1 (en) | 1994-08-25 |
AU637389B2 (en) | 1993-05-27 |
GB8917029D0 (en) | 1989-09-13 |
EP0410713A1 (en) | 1991-01-30 |
EP0484406B1 (en) | 1994-07-20 |
AU6071090A (en) | 1991-02-22 |
US5245010A (en) | 1993-09-14 |
IE65588B1 (en) | 1995-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5650488A (en) | Polypeptide inhibitor of the replication of HSV | |
Malone et al. | Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins | |
Smibert et al. | Herpes simplex virus VP16 forms a complex with the virion host shutoff protein vhs | |
US5656599A (en) | Papillomavirus E2 trans-activation repressors | |
Digard et al. | The extreme C terminus of herpes simplex virus DNA polymerase is crucial for functional interaction with processivity factor UL42 and for viral replication | |
US6200577B1 (en) | Anti-herpesviral agents and assays therefor | |
JP4612071B2 (en) | Epstein-Barr virus peptide and antibody against the peptide | |
US20050164163A1 (en) | Assay for screening for an anti-viral agent | |
US5306635A (en) | DNA encoding immunogenic gpIII glycoprotein of varicella-zoster virus | |
Mardon et al. | Frameshift and intragenic suppressor mutations in a Rous sarcoma provirus suggest src encodes two proteins | |
US5821339A (en) | Compositions and methods for treatment of herpesvirus infections | |
AU637389B2 (en) | Polypeptide inhibitor of viral replication | |
Xiong et al. | Detection in vivo of a new gene product (gene III) of cauliflower mosaic virus | |
Spatz et al. | Mutational analysis of ICP0R, a transrepressor protein created by alternative splicing of the ICP0 gene of herpes simplex virus type 1 | |
JPH07501710A (en) | Epstein-Barr virus peptides and antibodies against these peptides | |
Munch et al. | Interaction of the 89K murine cytomegalovirus immediate-early protein with core histones | |
US5041536A (en) | Pseudorabies virus (PRV) gene | |
Kirchherr et al. | Expression of the cauliflower mosaic virus capsid gene in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2063801 Country of ref document: CA Ref document number: 1990911594 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990911594 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990911594 Country of ref document: EP |